Applying the CRISPR/Cas9 for Treating Human and Animal Diseases – Comprehensive Review-Reference-Cited by-全球学者库

Applying the CRISPR/Cas9 for Treating Human and Animal Diseases – Comprehensive Review

Published:2023-11-01 Issue:4 Volume:23 Page:979-992
ISSN:2300-8733
Container-title:Annals of Animal Science
language:en
Short-container-title:

Author:

Abdelnour Sameh A.¹,Salaka Afnan S.²,Shakoori Afnan M.²,Alsaffar Nida³,Hassanin Abdallah A.⁴,Abukhalil Mohammad H.⁵⁶,Abd El-Hack Mohamed E.⁷

Affiliation:

1. 1 Animal Production Department, Faculty of Agriculture , Zagazig University , Zagazig , , Egypt

2. 2 Laboratory Medicine Department, Faculty of Applied Medical Sciences , Umm Al-Qura University , Makkah , Kingdom of Saudi Arabia

3. 3 Biochemistry and Molecular Biology, Mohammed Al-Mana College for Medical Sciences , Dammam , Kingdom of Saudi Arabia

4. 4 Genetics Department, Faculty of Agriculture , Zagazig University , Zagazig , , Egypt

5. 5 Department of Medical Analysis , Princess Aisha Bint Al-Hussein College of Nursing and Health Sciences, Al-Hussein Bin Talal University , Ma’an , Jordan

6. 6 Department of Biology, College of Science , Al-Hussein Bin Talal University , Ma’an , Jordan

7. 7 Poultry Department, Faculty of Agriculture , Zagazig University , Zagazig , Egypt

Abstract

Abstract Recently, genome editing tools have been extensively used in many biomedical sciences. The gene editing system is applied to modify the dnA sequences in the cellular system to comprehend their physiological response. A developing genome editing technology like clustered regularly short palindromic repeats (CRISPR) is widely used in medical sciences. CRISPR and CRISPR-associated protein 9 (CRISPR/Cas9) system is being exploited to edit any DNA mutations related to inherited ailments to investigate in animals (in vivo) and cell lines (in vitro). Remarkably, CRISPR/Cas9 could be employed to examine treatments of many human genetic diseases such as cystic fibrosis, tyrosinemia, phenylketonuria, muscular dystrophy, Parkinson’s disease, retinoschisis, hemophilia, β-thalassemia and atherosclerosis. Moreover, CRISPR/Cas9 was used for disease resistance such as tuberculosis, Johne’s diseases, chronic enteritis, and brucellosis in animals. Finally, this review discusses existing progress in treating hereditary diseases using CRISPR/Cas9 technology and the high points accompanying obstacles.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/aoas-2023-0009

Reference80 articles.

1. Anders C., Niewoehner O., Duerst A., Jinek M. (2014). Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature, 513: 569–573.

2. Axelsen T.M., Woldbye D.P. (2018). Gene therapy for Parkinson’s disease, an update. J. Parkinson’s Dis., 8: 195–215.

3. Bengtsson N.E., Hall J.K., Odom G.L., Phelps M.P., Andrus C.R., Hawkins R.D., Hauschka S.D., Chamberlain J.R., Chamberlain J.S. (2017). Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat. Commun., 8: 16007.

4. Bevacqua R.J., Fernandez-Martín R., Savy V., Canel N.G., Gismondi M.I., Kues W.A., Carlson D.F., Fahrenkrug S., Niemann H., Taboga O.A. (2016). Efficient edition of the bovine PRNP prion gene in somatic cells and IVF embryos using the CRISPR/Cas9 system. Theriogenology, 86: 1886–1896.

5. Bischoff N., Wimberger S., Maresca M., Brakebusch C. (2020). Improving precise CRISPR genome editing by small molecules: is there a magic potion? Cells, 9: 1318.